cardiology

Flecainide After PCI: 35 Years After CAST, Is It Time to Reconsider Class Ic Antiarrhythmics in Coronary Artery Disease?

cardiology

2026 ACC/AHA Dyslipidemia Guideline: A Comprehensive Pharmacotherapy Review

The 2026 ACC/AHA Dyslipidemia Guideline represents the most significant overhaul of lipid management since 2018 — introducing specific cholesterol targets and an expanded pharmacotherapeutic armamentarium.

PharmaCompass InPHARMation is for educational purposes only and does not constitute medical advice. Always verify clinical information before applying to patient care. Full Disclaimer | © 2026 PharmaCompass Education, LLC